Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes the clinical, trichoscopic, and histopathological features of alopecia types associated with cutaneous and systemic lupus erythematosus and explores their links to disease activity, but it reports no new clinical results.

This study suggests that fatigue, joint pain, and light sensitivity are significant impacts for systemic lupus erythematosus patients, highlighting areas of unmet need in current treatment options.

This case report describes a 19-year-old male with systemic lupus erythematosus presenting with an unusual combination of mucinous nonscarring alopecia and papulonodular mucinosis, noted by mucin deposition in skin lesions, which responded partially to treatment with hydroxychloroquine and prednisolone.

This study found that 59.7% of lupus patients self-reported alopecia, which was linked to anti-Ro antibody presence and cutaneous SLE symptoms but not to age, ethnicity, or medication.

This study found that self-reported alopecia was common in lupus patients, often characterized by changes in hair texture and volume, and was associated with anti-Ro antibodies and significant anxiety.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

In this study of SLE patients in North-East India, oral ulcers were reported as the most common cutaneous manifestation, followed by malar rash and photosensitivity.

This article reviews the current ACR classification criteria for systemic lupus erythematosus, highlighting their dermatologic limitations, and proposes guidelines for a study to update these criteria.

This article reviews the classification and treatment of cutaneous manifestations in systemic lupus erythematosus, highlighting the importance of monitoring for disease progression and reports no new clinical results.

This review discusses genome-wide association studies in dermatology, noting that variants linked to risk for 10 skin complex diseases have been identified, with potential implications for diagnostics and management; it reports no new clinical results.

This case report presents a rare instance of coexistent tumid lupus erythematosus and systemic lupus erythematosus in a patient, with symptom improvement noted after hydroxychloroquine treatment.

In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

This case report describes a patient with systemic lupus erythematosus who developed Degos disease and non-scarring alopecia, highlighting dermoscopy's role in diagnosis and treatment prognosis.

This announcement in the Australasian Journal of Dermatology provides no new research findings or study results.

This study reviews the types of alopecia associated with lupus erythematosus and discusses treatment challenges, highlighting that non-scarring alopecia is specific to systemic lupus while chronic cutaneous lupus can cause scarring alopecia, with topical corticosteroids and oral antimalarials as primary treatments for cutaneous lupus erythematosus.

This study provides an updated overview of non-scarring alopecia in lupus erythematosus patients, revealing that diffuse/patchy NSA and lupus hair are strongly associated with systemic activity and respond well to SLE therapy, while progression to scarring alopecia was rare.

This report presents two cases of systemic lupus in male patients with a distinct form of alopecia that combines both scarring and non-scarring elements, highlighting the variability in lupus-related hair loss presentations.

This article reviews the characteristics of Lupus Erythematosus Panniculitis as a rare variant of Chronic Cutaneous Lupus Erythematosus, with no new clinical results reported.

This case report describes a patient with systemic lupus erythematosus who developed leukocytoclastic vasculitis, suggesting this skin condition may be related to SLE exacerbation.

This study found that cutaneous manifestations, including specific skin lesions and oral ulceration, are common early indicators of SLE and may aid in its diagnosis and management.

This study found that cutaneous signs such as chilblains and urticaria were notably common in British patients with systemic lupus erythematosus, while subacute cutaneous lesions were less frequent.

This article discusses the classification and significance of cutaneous manifestations in systemic lupus erythematosus, emphasizing the importance of recognizing these skin features for disease management, but reports no new clinical results.

This review describes the types of skin lesions associated with systemic lupus erythematosus, discussing their histopathological features, serologic associations, pathogenesis, and prognostic implications.

This article reviews the characteristics and classification criteria of cutaneous lupus erythematosus and reports no new clinical findings.

This study found that simultaneous presence of specific and nonspecific skin lesions, or having three or more types of skin lesions, was associated with increased systemic activity of systemic lupus erythematosus.

This review discusses the varied cutaneous manifestations of Systemic Lupus Erythematosus and outlines treatment approaches, but it reports no new clinical findings.

This case report suggests that Rituximab and high-dose immunosuppressive therapy may be effective for treating severe cutaneous lupus erythematosus like TEN-like ACLE, leading to remission and recovery.